H ypertension is 1 of the most important risk factors for cardiovascular disease, and it is projected that 1.5 billion people in the world will have hypertension by 2025.
ties that include the inhibition of fibrosis and vascular smooth muscle proliferation, promotion of cardiomyocyte relaxation, and stimulation of endothelial cell regeneration. 3 Recent studies also suggest that CNP may modulate vascular tone and BP via mechanisms targeting not only GC-B, but involving the natriuretic peptide clearance receptor. 11, 12 Although CNP is the natriuretic peptide most susceptible to degradation by neprilysin, elevations in plasma CNP are associated with cardiovascular comorbidities and are indicative of myocardial infarction risk in the general population. 13 In the current issue of Circulation, Špiranec and colleagues 14 provide intriguing new insights that markedly advance our understanding of the crucial, and to date unrecognized, role for the CNP/GC-B/cGMP pathway in BP regulation and cardiovascular homeostasis. These investigators performed a series of elegant experimental studies that provide novel evidence for a key role of the CNP/GC-B/cGMP signaling system in regulating microcirculatory vascular tone and BP with a special function within the pericyte, which are fascinating contractile cells that wrap around capillaries and venules ( Figure) . 15 Using state-of-the-art intravital microscopic analyses, the authors clearly reveal the vasodilatory effect of CNP, both in the absence and presence of the potent endothelium-derived vasoconstrictor endothelin 1. This occurs specifically in precapillary arterioles and the capillary microcirculation (arterial vessels with lumen diameters of 15 µm or less), and, most intriguingly, CNP-mediated vasodilation occurred at the site of the pericytes. It is notable that this interaction between CNP and the pericyte was previously unsuspected. Furthermore, CNP generated intracellular cGMP in a dose-dependent manner in both cultured human and mouse pericytes and in endothelial cells, with pericytes having the ability to generate CNP-mediated cGMP to a greater extent than endothelial cells. Using unique transgenic mouse models with pericyte or endothelial cell-restricted deletion of GC-B, the cognate receptor for CNP, the authors demonstrate that the vasodilatory effects of CNP, with and without endothelin 1 constriction, are lost in pericyte-restricted GC-B knockout mice but preserved in mice with endothelial cell-restricted GC-B silencing. A similar CNP vasodilatory response was also observed in the explanted retinal microcirculation, which lacks active pressure-dependent blood flow, in both of these 2 preclinical models.
To further support the importance of the pericyte GC-B/cGMP system as playing a role in regulating BP, mice that lacked the GC-B receptor specifically in the pericyte manifested mildly elevated, yet chronic, arterial hypertension that was attributed to elevated total peripheral resistance, as renal function was preserved. Importantly, the authors provide convincing evidence that A, Microvascular circulatory bed that includes the arteriole, precapillary arteriole, capillaries, and venules where the physiological interactions between endothelial-derived CNP, GC-B, and the pericyte occur to regulate blood pressure (BP). B, Magnification of a cross-section of microcirculation with interaction of the pericyte. Špiranec and coworkers 14 report a novel mechanism of BP regulation via the GC-B/cGMP system on pericytes specifically localized on the precapillary arterioles and capillary. The authors demonstrate that pericyte-specific GC-B activation, by CNP, mediates a reduction in pericyte contraction through cGMP-dependent protein kinase I and its downstream target cytoskeleton-associated vasodilator activated phosphoprotein as well as enhancing cAMP levels through the inhibition of PDE3A. These molecular actions increase microvascular vasodilation through pericyte relaxation, thus lowering arterial pressure. Diminished pericyte GC-B/cGMP activation attributable to a CNP deficiency may contribute to hypertension. Thus, augmentation of the pericyte GC-B/cGMP system, via reduction in CNP degradation or use of CNP-based analogues, reduces BP and hypertension. BM indicates basal membrane; cAMP, 3',5'-cyclic adenosine monophosphate; EC, endothelial cell; P, pericyte; and PDE3A, phosphodiesterase 3A.
the CNP/GC-B/cGMP signaling axis prevents endothelin 1-induced elevation in pericyte calcium levels and contraction via activation of cGMP-dependent protein kinase I, and its downstream target cytoskeleton-associated vasodilator-activated phosphoprotein, as well as by enhancing cAMP levels through inhibition of PDE3A. Collectively, these new findings enhance our understanding of the novel cardiovascular actions of the CNP/GC-B/ cGMP axis with significant relevance to a potential role as both mediator and molecular target in hypertension.
So where do we go from here following these important and in-depth studies? One possible first step is to chronically treat both the endothelial GC-B and pericyte GC-B knockout mice with CNP or CNP-based analogues to determine whether BP is altered in either of these genetically modified mouse models. It is tempting to speculate that CNP treatment in endothelial GC-B knockout mice will elicit a mild hypotensive effect, as the GC-B receptor in pericytes remains intact, thus retaining the ability to reduce microcirculatory peripheral resistance. However, mice exposed to chronic CNP therapy in the setting of pericyte-restricted GC-B knockout could either remain mildly hypertensive or elevations of BP may be attenuated via non-GC-B/cGMP mechanisms such as through the natriuretic peptide clearance receptor, as previously reported.
11 Additionally, in-depth studies to interrogate the pericyte and GC-B/cGMP system in other experimental models of human hypertension, such as the spontaneously hypertensive rat or angiotensin II-induced hypertension, may also be worthwhile. Lastly, taking a broad view of the NP/GC/cGMP pathways as a whole (eg, ANP, BNP, and CNP), therapies that augment all of these key hormones, either via use of a neprilysin inhibitor or novel NP analogues that potentiate both the GC-A and GC-B receptors, may be efficacious therapeutic strategies for human hypertension. Furthermore, studies in the general population and in hypertensive subjects should re-examine the role of circulating CNP, its possible relationship with hypertension, and a potential association between hypertension and genetic variants of the CNP/GC-B/cGMP signaling pathway, including relevant phosphodiesterases.
What we know unequivocally is that hypertension is a challenging disease, one which is in dire need of both novel therapeutics and continuation of research addressing its complex pathophysiology. Spiranec and coworkers are to be congratulated for identifying a unique mechanism by which BP is regulated via the CNP/GC-B/cGMP pathway in the pericyte and microcirculation. Furthermore, this sophisticated study underscores important cross-talk between the endothelium and pericyte. With future studies, novel CNP/GC-B/ cGMP potentiating drugs may offer additional hope in our quest to reduce the global burden of hypertension and cardiovascular disease.
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